This trial is testing a new hepatitis B vaccine to see if it works better than the current one for people who didn't respond to the current one.
1 Primary · 2 Secondary · Reporting Duration: one month after dose 2 (up to 84 days on study)
130 Total Participants · 1 Treatment Group
Primary Treatment: Recombinant hepatitis B vaccine with CpG adjuvant · No Placebo Group · Phase 4
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|University of Wisconsin||100.0%|
|Did not meet criteria||100.0%|